Hypothesis

We propose that brief, low‑intensity pain episodes activate a conserved hormetic cascade that enhances lysosomal function and completes autophagic flux, promoting cellular repair and longevity. In contrast, sustained high‑intensity pain drives maladaptive signaling that impairs lysosomal activity, blocks autophagosome‑lysosome fusion, and accelerates aging. Pharmacological analgesia that indiscriminately suppresses all pain signals may therefore blunt the beneficial hormetic window while leaving maladaptive pathways active.

Mechanistic Rationale

Low‑grade nociceptive input transiently elevates intracellular calcium and activates the AMPK‑ULK1 axis, initiating phagophore formation. Simultaneously, a modest rise in cytosolic ROS stimulates TFEB nuclear translocation, upregulating lysosomal biogenesis genes (e.g., LAMP1, CATHEPSIN D). This coordinated increase in autophagosome supply and lysosomal capacity ensures efficient cargo degradation—a hallmark of hormetic stress observed in brief hypoxia3 and fasting.

When pain becomes chronic, persistent calcium influx and pro‑inflammatory cytokine release (IL‑1β, TNF‑α) sustain mTORC1 activity and inhibit TFEB through phosphorylation by ERK1/2. Lysosomal acidification falls, cathepsin activity declines, and autophagosomes accumulate without degradation, producing the “blocked flux” phenotype linked to senescence4. Analgesics such as opioids and NSAIDs further modulate these pathways: opioids inhibit neuronal calcium channels, reducing the calcium signal needed for AMPK activation, while NSAIDs suppress prostaglandin‑mediated TFEB activation56. Thus, analgesia may unintentionally shift the balance from hormetic to pathological signaling.

Testable Predictions

1. Mice receiving intermittent, low‑intensity mechanical paw pressure (2 min, 0.5 g, three times daily) will show increased LC3‑II turnover, elevated LAMP1 intensity, and extended median lifespan compared with untreated controls.
2. Mice subjected to continuous high‑intensity pressure (2 h, 5 g) will exhibit reduced autophagic flux (accumulation of p62/LDLC despite LC3‑II rise) and shortened lifespan.
3. Administration of a µ‑opioid antagonist during intermittent pain will enhance lysosomal TFEB nuclear localization and autophagic completion, whereas the same antagonist during continuous pain will have no effect on flux.
4. In human peripheral blood mononuclear cells, serum from individuals reporting occasional exercise‑induced muscle soreness will correlate with higher lysosomal cathepsin activity and lower senescence‑associated β‑galactosidase than serum from chronic pain patients.

Experimental Approach

• Use C57BL/6 mice, split into four groups: (a) intermittent low‑grade pain, (b) continuous high‑grade pain, (c) intermittent pain + opioid antagonist, (d) continuous pain + opioid antagonist. Monitor pain behavior via von Frey testing, then assess autophagy flux in liver and brain using tandem mRFP‑GFP‑LC3 reporter and lysosomal activity with LysoTracker. Survival curves are generated over 30 months.
• For human validation, collect serum from volunteers stratified by self‑reported pain frequency (none, occasional, frequent, chronic). Measure cathepsin D/L activity, p62 levels, and SASP markers via ELISA and flow cytometry.

Potential Outcomes and Falsifiability

If intermittent pain improves autophagic completion and longevity while continuous pain impairs it, and if opioid blockade selectively augments the intermittent effect, the hypothesis is supported. Failure to observe differential lysosomal TFEB activation or autophagic flux between intermittent and chronic paradigms, or lack of lifespan divergence, would falsify the claim that pain intensity and duration dictate hormetic versus pathological outcomes.